DiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $10.00 at HC Wainwright

Posted by ABMN Staff on Mar 20th, 2025

DiaMedica Therapeutics (NASDAQ:DMAC – Free Report) had its price objective upped by HC Wainwright from $7.00 to $10.00 in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

DiaMedica Therapeutics Stock Up 0.6 %

DMAC opened at $5.24 on Wednesday. The stock has a market cap of $224.07 million, a PE ratio of -9.36 and a beta of 1.52. DiaMedica Therapeutics has a 52 week low of $2.14 and a 52 week high of $6.82. The business’s fifty day simple moving average is $5.95 and its 200 day simple moving average is $5.10.

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). As a group, equities analysts anticipate that DiaMedica Therapeutics will post -0.59 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of DMAC. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of DiaMedica Therapeutics during the third quarter valued at about $40,000. Balyasny Asset Management L.P. purchased a new stake in shares of DiaMedica Therapeutics during the fourth quarter worth about $79,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of DiaMedica Therapeutics during the fourth quarter worth about $81,000. Raymond James Financial Inc. purchased a new stake in shares of DiaMedica Therapeutics during the fourth quarter worth about $83,000. Finally, Bank of Montreal Can purchased a new stake in shares of DiaMedica Therapeutics during the fourth quarter worth about $84,000. 10.12% of the stock is owned by institutional investors.

DiaMedica Therapeutics Company Profile

(Get Free Report)

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.